Maltodextrin
Maltodextrin is an unknown pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fortical | New Drug Application | 2010-01-15 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
1339 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | 11 | 6 | 14 | 23 | 35 | 89 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 4 | 4 | 2 | 74 | 84 |
| Healthy volunteers/patients | — | — | — | 11 | 4 | 2 | 3 | 67 | 84 |
| Overweight | D050177 | — | E66.3 | 2 | 4 | 1 | 2 | 37 | 44 |
| Inflammation | D007249 | MP_0001845 | — | 2 | 1 | 5 | 1 | 32 | 41 |
| Syndrome | D013577 | — | — | 5 | 10 | 3 | 1 | 28 | 40 |
| Constipation | D003248 | HP_0002019 | K59.0 | 1 | 4 | 2 | 2 | 31 | 40 |
| Insulin resistance | D007333 | HP_0000855 | — | 1 | 5 | 2 | 2 | 25 | 33 |
| Infections | D007239 | EFO_0000544 | — | — | 6 | 3 | 1 | 22 | 32 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | 1 | 4 | 1 | 2 | 25 | 32 |
Show 76 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | 3 | 3 | — | 32 | 37 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | 2 | 1 | — | 22 | 24 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 2 | 2 | 1 | — | 21 | 24 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 1 | 1 | 1 | — | 20 | 22 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | 1 | 1 | — | 20 | 22 |
| Communicable diseases | D003141 | — | — | — | 4 | 1 | — | 17 | 22 |
| Hypertension | D006973 | EFO_0000537 | I10 | 6 | 3 | 1 | — | 13 | 20 |
| Gastrointestinal diseases | D005767 | — | — | 1 | — | 1 | — | 18 | 20 |
| Osteoporosis | D010024 | HP_0000939 | M81.0 | 3 | 3 | 7 | — | 7 | 19 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 1 | — | 2 | — | 13 | 16 |
Show 62 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aging | D000375 | GO_0007568 | R41.81 | 2 | 1 | — | — | 15 | 18 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | 2 | — | — | 11 | 14 |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | 1 | — | — | 11 | 12 |
| Respiratory tract infections | D012141 | — | J06.9 | 1 | 3 | — | — | 8 | 12 |
| Thyroid neoplasms | D013964 | EFO_0003841 | — | 2 | 4 | — | — | 3 | 9 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | 2 | 4 | — | — | 3 | 9 |
| Diet therapy | D004035 | — | — | — | 1 | — | — | 8 | 9 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 3 | — | — | 5 | 8 |
| Digestive signs and symptoms | D012817 | — | — | 3 | 2 | — | — | 5 | 8 |
| Heart failure | D006333 | HP_0001635 | I50 | 2 | 2 | — | — | 4 | 8 |
Show 81 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | 19 | 20 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | 1 | — | — | — | 10 | 11 |
| Weight loss | D015431 | HP_0001824 | — | 2 | — | — | — | 8 | 10 |
| Oxidative stress | D018384 | EFO_1001905 | — | 1 | — | — | — | 7 | 8 |
| Microbiota | D064307 | — | — | 1 | — | — | — | 6 | 7 |
| Body composition | D001823 | — | — | 1 | — | — | — | 5 | 6 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | 2 | — | — | — | 4 | 6 |
| Food hypersensitivity | D005512 | EFO_1001890 | — | 1 | — | — | — | 4 | 5 |
| Protein deficiency | D011488 | — | — | 1 | — | — | — | 3 | 4 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | — | — | — | 3 | 4 |
Show 32 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 12 | 12 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | — | 10 | 10 |
| Iron-deficiency anemia | D018798 | HP_0001891 | D50 | — | — | — | — | 9 | 9 |
| Healthy diet | D000072001 | — | — | — | — | — | — | 9 | 9 |
| Affect | D000339 | — | — | — | — | — | — | 9 | 9 |
| Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | — | 8 | 8 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 8 | 8 |
| Muscular atrophy | D009133 | HP_0003202 | — | — | — | — | — | 7 | 7 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 7 | 7 |
| Digestive system diseases | D004066 | HP_0011024 | K92.9 | — | — | — | — | 7 | 7 |
Show 295 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Maltodextrin |
| INN | — |
| Description | Maltodextrin is a name shared by two different families of chemicals. Both families are glucose polymers (called dextrose or dextrins), but have little chemical or nutritional similarity.
|
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >5BJZ:C,D|Synthetic antibody, Fab fragment, Heavy Chain
EISEVQLVESGGGLVQPGGSLRLSCAASGFNLSSSSIHWVRQAPGKGLEWVASIYSYYGSTSYADSVKGRFTISADTSKN
TAYLQMNSLRAEDTAVYYCAREYHSYWSYSWWPRVGLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVK
DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT
>5BJZ:L,H|Synthetic antibody, Fab fragment, Light Chain
SDIQMTQSPSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQ
PEDFATYYCQQASLTALLTFGQGTKVEIKRTVAAPSVFIFPPSDSQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGN
SQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
115 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use